A well being employee holds blood samples throughout scientific trials for a Covid-19 vaccine at Analysis Facilities of America in Hollywood, Florida, on Wednesday, Sept. 9, 2020.
Eva Marie Uzcategui | Bloomberg | Getty Photographs
Pfizer mentioned on Friday it may apply for U.S. emergency use of its Covid-19 vaccine candidate being developed together with Germany’s BioNTech as quickly as a security milestone is achieved within the third week of November.
The U.S. Meals and Drug Administration has mentioned it needs at the least two months of security information earlier than authorizing emergency use of any experimental coronavirus vaccine.
Primarily based on present trial enrollment and dosing tempo, Pfizer expects to have that security information within the third week of November, Chief Government Officer Albert Bourla mentioned in an announcement.
Pfizer had mentioned beforehand that it anticipated late-stage trial information in October.
This story is growing. Please verify again for updates.